1
|
Gökçek Ö, Koptay MS, Özkan SB. Ultrasonographic characteristics of testicular renal cell carcinoma metastasis: A case report and literature review. JOURNAL OF CLINICAL ULTRASOUND : JCU 2024. [PMID: 38822668 DOI: 10.1002/jcu.23742] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/26/2024] [Accepted: 05/05/2024] [Indexed: 06/03/2024]
Abstract
Renal cell carcinoma (RCC) extremely rarely metastasizes to the testis. To date, only three reports have documented bilateral testicular metastasis of RCC. Here, we review the ultrasonographic characteristics of testicular metastasis of renal cell carcinoma cases in the literature and present a 43-year-old patient with von Hippel-Lindau (VHL) disease who was diagnosed with bilateral testicular metastasis of RCC many years after nephrectomy, with ultrasonographic-pathological correlation.
Collapse
Affiliation(s)
- Özcan Gökçek
- Radiology, Health Sciences University Ankara Atatürk Sanatorium Training and Research Hospital, Ankara, Turkey
| | - Medine Sinem Koptay
- Radiology, Health Sciences University Ankara Atatürk Sanatorium Training and Research Hospital, Ankara, Turkey
| | - Simay Bozpınar Özkan
- Pathology, Health Sciences University Ankara Atatürk Sanatorium Training and Research Hospital, Ankara, Turkey
| |
Collapse
|
2
|
Pliszka A, Rajda S, Wawrzyniak A, Walocha J, Polguj M, Wysiadecki G, Clarke E, Golberg M, Zarzecki M, Balawender K. Testicular Metastasis from Renal Cell Carcinoma: A Systematic Review. J Clin Med 2023; 12:5636. [PMID: 37685703 PMCID: PMC10488956 DOI: 10.3390/jcm12175636] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2023] [Revised: 08/23/2023] [Accepted: 08/27/2023] [Indexed: 09/10/2023] Open
Abstract
Approximately one-third of renal cell carcinoma (RCC) is recognized in its metastatic stage. This systematic review aimed to summarize knowledge on the occurrence and treatment of testicular RCC metastasis. The literature search was performed by two authors independently, with the use of main electronic medical databases (Science Direct, Web of Science, and PubMed) until March 2023 to identify relevant articles that could potentially contribute to this review. Neither language nor publication dates were set as limits. Although we found a total of 51 case reports, only 31 of them contained all the required information. Testicular metastasis in patients with RCC suggests a late stage of the disease. Moreover, it usually does not present typical systemic or specific symptoms except for swelling and enlargement of the affected testis. Knowledge of the possibility of such variants of RCC metastases will allow a clinician to make an appropriate diagnosis and implement adequate treatment without delay, which is crucial in the management of neoplastic disease.
Collapse
Affiliation(s)
- Anna Pliszka
- Department of Normal and Clinical Anatomy, Institute of Medical Sciences, Medical College of Rzeszow University, 35-315 Rzeszow, Poland; (A.P.); (S.R.)
| | - Sebastian Rajda
- Department of Normal and Clinical Anatomy, Institute of Medical Sciences, Medical College of Rzeszow University, 35-315 Rzeszow, Poland; (A.P.); (S.R.)
| | - Agata Wawrzyniak
- Department of Histology and Embryology, Institute of Medical Sciences, Medical College of Rzeszow University, 35-315 Rzeszow, Poland;
| | - Jerzy Walocha
- Department of Anatomy, Jagiellonian University Medical College Cracow, 33-332 Kraków, Poland;
- Youthoria, Youth Research Organization, 33-332 Kraków, Poland
| | - Michał Polguj
- Department of Normal and Clinical Anatomy, Medical University of Lodz, 90-752 Łódź, Poland; (M.P.); (E.C.)
| | - Grzegorz Wysiadecki
- Department of Normal and Clinical Anatomy, Medical University of Lodz, 90-752 Łódź, Poland; (M.P.); (E.C.)
| | - Edward Clarke
- Department of Normal and Clinical Anatomy, Medical University of Lodz, 90-752 Łódź, Poland; (M.P.); (E.C.)
| | - Michał Golberg
- Department of Histology and Embryology, Medical University of Lodz, 90-752 Łódź, Poland;
| | - Michał Zarzecki
- Department of Neonatology and Neonatal Intensive Care, The Children’s Memorial Health Institute, 04-730 Warsaw, Poland;
| | - Krzysztof Balawender
- Department of Normal and Clinical Anatomy, Institute of Medical Sciences, Medical College of Rzeszow University, 35-315 Rzeszow, Poland; (A.P.); (S.R.)
- Clinical Department of Urology and Urological Oncology, Municipal Hospital in Rzeszow, 35-241 Rzeszow, Poland
| |
Collapse
|
3
|
Repp ML, Alvarez RA, Arevalo-Salazar DE, Kotagiri R. Metastatic Renal Cell Carcinoma and Unforeseen Adrenal Insufficiency: A Case Report and Literature Review. Cureus 2023; 15:e35265. [PMID: 36968872 PMCID: PMC10035604 DOI: 10.7759/cureus.35265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/21/2023] [Indexed: 02/23/2023] Open
Abstract
Renal cell carcinoma (RCC) can metastasize to nearly every organ, yet rarely metastasizes to the adrenal glands despite their anatomical proximity. Adrenal metastases are typically incidental findings on medical imaging and are vastly clinically asymptomatic. The adrenal glands can maintain hormonal homeostasis if a tenth of total adrenal gland function is preserved. We present a patient with synchronous bilateral adrenal metastases from RCC with rapid and unexpected development of adrenal insufficiency (AI).
Collapse
Affiliation(s)
- Matthew L Repp
- Medical School, University of Arizona College of Medicine, Tucson, USA
| | - Rodrigo A Alvarez
- Internal Medicine, University of Arizona College of Medicine, Tucson, USA
| | | | - Rajesh Kotagiri
- Internal Medicine, University of Arizona College of Medicine, Tucson, USA
| |
Collapse
|
4
|
Hanusek K, Poletajew S, Kryst P, Piekiełko-Witkowska A, Bogusławska J. piRNAs and PIWI Proteins as Diagnostic and Prognostic Markers of Genitourinary Cancers. Biomolecules 2022; 12:biom12020186. [PMID: 35204687 PMCID: PMC8869487 DOI: 10.3390/biom12020186] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2021] [Revised: 01/14/2022] [Accepted: 01/18/2022] [Indexed: 12/30/2022] Open
Abstract
piRNAs (PIWI-interacting RNAs) are small non-coding RNAs capable of regulation of transposon and gene expression. piRNAs utilise multiple mechanisms to affect gene expression, which makes them potentially more powerful regulators than microRNAs. The mechanisms by which piRNAs regulate transposon and gene expression include DNA methylation, histone modifications, and mRNA degradation. Genitourinary cancers (GC) are a large group of neoplasms that differ by their incidence, clinical course, biology, and prognosis for patients. Regardless of the GC type, metastatic disease remains a key therapeutic challenge, largely affecting patients’ survival rates. Recent studies indicate that piRNAs could serve as potentially useful biomarkers allowing for early cancer detection and therapeutic interventions at the stage of non-advanced tumour, improving patient’s outcomes. Furthermore, studies in prostate cancer show that piRNAs contribute to cancer progression by affecting key oncogenic pathways such as PI3K/AKT. Here, we discuss recent findings on biogenesis, mechanisms of action and the role of piRNAs and the associated PIWI proteins in GC. We also present tools that may be useful for studies on the functioning of piRNAs in cancers.
Collapse
Affiliation(s)
- Karolina Hanusek
- Centre of Postgraduate Medical Education, Department of Biochemistry and Molecular Biology, 01-813 Warsaw, Poland;
| | - Sławomir Poletajew
- Centre of Postgraduate Medical Education, II Department of Urology, 01-813 Warsaw, Poland; (S.P.); (P.K.)
| | - Piotr Kryst
- Centre of Postgraduate Medical Education, II Department of Urology, 01-813 Warsaw, Poland; (S.P.); (P.K.)
| | - Agnieszka Piekiełko-Witkowska
- Centre of Postgraduate Medical Education, Department of Biochemistry and Molecular Biology, 01-813 Warsaw, Poland;
- Correspondence: (A.P.-W.); (J.B.)
| | - Joanna Bogusławska
- Centre of Postgraduate Medical Education, Department of Biochemistry and Molecular Biology, 01-813 Warsaw, Poland;
- Correspondence: (A.P.-W.); (J.B.)
| |
Collapse
|
5
|
Cooley LS, Rudewicz J, Souleyreau W, Emanuelli A, Alvarez-Arenas A, Clarke K, Falciani F, Dufies M, Lambrechts D, Modave E, Chalopin-Fillot D, Pineau R, Ambrosetti D, Bernhard JC, Ravaud A, Négrier S, Ferrero JM, Pagès G, Benzekry S, Nikolski M, Bikfalvi A. Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression. Mol Cancer 2021; 20:136. [PMID: 34670568 PMCID: PMC8527701 DOI: 10.1186/s12943-021-01416-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2021] [Accepted: 08/30/2021] [Indexed: 01/22/2023] Open
Abstract
BACKGROUND Renal Cell Carcinoma (RCC) is difficult to treat with 5-year survival rate of 10% in metastatic patients. Main reasons of therapy failure are lack of validated biomarkers and scarce knowledge of the biological processes occurring during RCC progression. Thus, the investigation of mechanisms regulating RCC progression is fundamental to improve RCC therapy. METHODS In order to identify molecular markers and gene processes involved in the steps of RCC progression, we generated several cell lines of higher aggressiveness by serially passaging mouse renal cancer RENCA cells in mice and, concomitantly, performed functional genomics analysis of the cells. Multiple cell lines depicting the major steps of tumor progression (including primary tumor growth, survival in the blood circulation and metastatic spread) were generated and analyzed by large-scale transcriptome, genome and methylome analyses. Furthermore, we performed clinical correlations of our datasets. Finally we conducted a computational analysis for predicting the time to relapse based on our molecular data. RESULTS Through in vivo passaging, RENCA cells showed increased aggressiveness by reducing mice survival, enhancing primary tumor growth and lung metastases formation. In addition, transcriptome and methylome analyses showed distinct clustering of the cell lines without genomic variation. Distinct signatures of tumor aggressiveness were revealed and validated in different patient cohorts. In particular, we identified SAA2 and CFB as soluble prognostic and predictive biomarkers of the therapeutic response. Machine learning and mathematical modeling confirmed the importance of CFB and SAA2 together, which had the highest impact on distant metastasis-free survival. From these data sets, a computational model predicting tumor progression and relapse was developed and validated. These results are of great translational significance. CONCLUSION A combination of experimental and mathematical modeling was able to generate meaningful data for the prediction of the clinical evolution of RCC.
Collapse
Affiliation(s)
- Lindsay S Cooley
- University of Bordeaux, LAMC, Pessac, France
- INSERM U1029, Pessac, France
| | - Justine Rudewicz
- University of Bordeaux, LAMC, Pessac, France
- INSERM U1029, Pessac, France
- Bordeaux Bioinformatics Center, CBiB, University of Bordeaux, Bordeaux, France
| | | | - Andrea Emanuelli
- University of Bordeaux, LAMC, Pessac, France
- INSERM U1029, Pessac, France
| | - Arturo Alvarez-Arenas
- Mathematical Modeling for Oncology Team, Inria Bordeaux Sud-Ouest, Talence, France
- Department of Mathematics, Mathematical Oncology Laboratory (MOLAB), Universidad de Castilla-La Mancha, Ciudad Real, Spain
| | - Kim Clarke
- University of Liverpool, Institute of Systems, Molecular and Integrative Biology, Liverpool, UK
| | - Francesco Falciani
- University of Liverpool, Institute of Systems, Molecular and Integrative Biology, Liverpool, UK
| | - Maeva Dufies
- Centre Scientifique de Monaco, Biomedical Department, Principality of Monaco, Monaco
- University Côte d'Azur, Institute for Research on Cancer and Aging of Nice (IRCAN), CNRS UMR 7284; INSERM U1081, Centre Antoine Lacassagne, Nice, France
| | | | - Elodie Modave
- VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium
| | - Domitille Chalopin-Fillot
- Bordeaux Bioinformatics Center, CBiB, University of Bordeaux, Bordeaux, France
- University of Bordeaux, IBGC, Bordeaux, France
| | - Raphael Pineau
- University of Bordeaux, "Service Commun des Animaleries", Bordeaux, France
| | - Damien Ambrosetti
- Centre Hospitalier Universitaire (CHU) de Nice, Hôpital Pasteur, Central laboratory of Pathology, Nice, France
| | | | - Alain Ravaud
- Centre Hospitalier Universitaire (CHU) de Bordeaux, service d'oncologie médicale, Bordeaux, France
| | | | - Jean-Marc Ferrero
- Centre Antoine Lacassagne, Clinical Research Department, Nice, France
| | - Gilles Pagès
- Centre Scientifique de Monaco, Biomedical Department, Principality of Monaco, Monaco
- University Côte d'Azur, Institute for Research on Cancer and Aging of Nice (IRCAN), CNRS UMR 7284; INSERM U1081, Centre Antoine Lacassagne, Nice, France
| | - Sebastien Benzekry
- Mathematical Modeling for Oncology Team, Inria Bordeaux Sud-Ouest, Talence, France
- COMPO team-project, Inria Sophia Antipolis and CRCM, Inserm U1068, CNRS UMR7258, Aix-Marseille University UM105, Institut Paoli-Calmettes, Marseille, France
| | - Macha Nikolski
- Bordeaux Bioinformatics Center, CBiB, University of Bordeaux, Bordeaux, France
- University of Bordeaux, IBGC, Bordeaux, France
| | - Andreas Bikfalvi
- University of Bordeaux, LAMC, Pessac, France.
- INSERM U1029, Pessac, France.
| |
Collapse
|
6
|
Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study. Anticancer Drugs 2020; 32:74-81. [PMID: 33290315 DOI: 10.1097/cad.0000000000001017] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Renal cell carcinoma (RCC) scenario has radically changed with the advent of immunotherapy; in this setting, the identification of predictive and prognostic factors represents an urgent clinical need to evaluate which patients are the best candidate for an immunotherapy approach. The aim of our study was to analyze the association between nivolumab in pretreated patients with metastatic RCC and clinicopathological features, metastatic sites, and clinical outcomes. A total of 37 patients treated between January 2017 and April 2020 in our institution were retrospectively evaluated. All patients received nivolumab as second- or later-line of therapy after progression on previous tyrosine kinase inhibitors. The primary outcomes were overall survival (OS) from immunotherapy start and OS from first-line start. Univariate analysis was performed through the log-rank test and a Cox regression proportional hazards model was employed in multivariable analysis. Of the 12 variables analyzed, 4 were significantly associated with prognoses at multivariate analysis. Cox proportional hazard ratio models confirmed that International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) risk group, liver metastases at diagnosis, and central nervous system (CNS) metastases at diagnosis were associated with worse OS with an estimated hazard ratio of 4.76 [95% confidence interval (CI), 2.05-19.8] for liver metastases and 2.27 (95% CI, 1.13-28.9) for CNS metastases. Pancreatic metastases at diagnosis were correlated to a better prognosis with an estimated hazard ratio of 0.15 (95% CI, 0.02-0.38). IMDC risk group, liver metastases at diagnosis, and CNS metastases at diagnosis may identify a population of patients treated with immunotherapy in second- or later-line associated with worse prognosis.
Collapse
|